Summa Health

And Adrian.

Hi, I'm Adrian Dan, and I am a medical director of bariatrics and fellowship director for the advanced GI MIS bariatric and foregut fellowship at a place called Summa Health System Northeast Ohio Medical University in Akron, Ohio.

And today, we're tackling a complication that every bariatric surgeon dreads, marginal ulcers.

It's one of the most common complications after Roux-en-Y gastric bypass, with the reported prevalence ranging widely from 0.6% to 16%, depending on the series, and about a pooled mean prevalence of around 4.6%.

No, it did.

And actually, from 2017 to 2022, I served on our local health system's board of directors, $1.4 billion health system, Summa Health.

It has its own insurance company, three or four hospitals, and several other business units.

So for six years, I was on the board, and for two of those years, I was the vice chair of the board.

I think it's not, like, we don't need to get too kind of caught up in one particular name or another one because I do think there's a lot of gray area between those, right? So, you know, the, the strategies that generally, like the strategies of venture capital firms, which are, you know, generally investing in You know, kind of early stage startup companies, um, which, you know, obviously could grow to be really, uh, really big, big companies that, that, you know, have broad impacts.

Um, you know, we've also seen venture capital firms that have, have bought out hospital companies, right? Um, General Catalyst, uh, last year or the year before acquired Summa Health, a, uh, hospital company in Ohio or a health system, a smaller health system in Ohio.

We've also seen hedge funds you mentioned as well.

Again, their, their strategies also vary that some might be focused on, you know, impacting publicly traded companies.

We're gonna be listening to, uh, Daryl Toll, who is the, uh, oversees Hatco.

Uh, and he's gonna tell the story of their, uh, acquisition of Summa Health Care and, and, and what they're learning from that.

Um, so we gotta get up there.

But before we go, Jay, I wanted to ask you a question.

They are asset light.

So it was considered very strange, but he went ahead, and we bought a, a healthcare system in Ohio, uh, called Summa Health.

And he did that because he wanted to show that innovating in the healthcare space is very difficult if you don't have-- You know, there are a lot of closed systems, there are a lot of hurdles if you're a newcomer and you wanna try to sort of inject your innovation into a closed system.

And so he wanted to prove that if you can sa- own the whole system and bring in all this technology, and Hippocratic is one of the companies that is active at Summa Health, um, and working at Summa Health, that you can really do all of the above that I mentioned, is better patient-- healthier and better patient outcomes, lower cost, less fraud, less waste, less abuse, and all the things that we're looking for and, and more abundance, to Munjal's point of moving from a scarcity to abundance model.

So, um, you know, education and we're, we're trying to really bring to light and bring to life that we, we really belie-- We're not just that we believe in it, we're practicing what we preach, and that these outcomes are going to be better for all.

And here's sort of, you could say, a real live sandbox to see, um, how we're doing that.